GenSight seeks cash as runway enters final year with gene therapy still stuck at EMA
GenSight seeks cash as runway enters final year with gene [...]
GenSight seeks cash as runway enters final year with gene [...]
Chutes & Ladders—Fierce Biotech launches Layoff Tracker amid dizzying number [...]
Pandemic tears up Biophytis’ plans, limiting data and blowing up [...]
Takeda spinout HilleVax goes public, a test of the choppy [...]
Jazz, Werewolf to howl at the moon together in $1.26B [...]
Gilead unveils pediatric drug development center in Ireland with 33 [...]
Athira board spares no punches to fend off proxy fight [...]
Path cleared for Iovance’s lead melanoma drug after FDA assay [...]
Merck looks to cardiovascular pipeline for $10B+ peak sales—and diversification [...]
Big Pharma partnerships, record $22.7B investment raise profile of regenerative [...]